Lianchun Xiao

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

  Journal of Clinical Oncology · 2026-06-11

• NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal

  Journal of Clinical Oncology · 2026-01-07 · 3 citations

• Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials

  Cancer · 2025-12-19 · 1 citations

• Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

  Leukemia · 2025-12-10 · 1 citations

• Circulating Fibroblast Growth Factor 21 (FGF21) as a Prognostic and Diagnostic Biomarker in Hepatocellular Carcinoma

  Journal of Hepatocellular Carcinoma · 2025-12-01

• A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias

  Journal of Hematology & Oncology · 2025-11-27 · 3 citations

• Autostent: a semi-automated approach to designing customized 3D-printed oral radiation stents for patients with head and neck cancer

  Radiation Oncology · 2025-11-17

• Safety and efficacy of liver-directed radiotherapy after chemoimmunotherapy for advanced cholangiocarcinoma: an early report from a large tertiary cancer center

  Journal of Gastrointestinal Oncology · 2025-10-01

• S2698 Circulating Fibroblast Growth Factor 21 (FGF21) as a Prognostic Biomarker in Hepatocellular Carcinoma

  The American Journal of Gastroenterology · 2025-10-01

• Ethnic and socioeconomic disparities in survival outcomes among patients under 65 years with intrahepatic cholangiocarcinoma: a SEER analysis

  Journal of Gastrointestinal Oncology · 2025-10-01

• 123P Cancer signal origin (CSO) prediction in cancer of unknown primary (CUP) syndrome (CRONUS) using circulating tumor DNA (ctDNA)

  Annals of Oncology · 2025-09-01 · 1 citations

• AML-420: Phase 1 Trial of Azacitidine, Venetoclax, and Allogeneic NK Cells in Acute Myeloid Leukemia (ADVENT-AML): Results From Dose-Escalation Phase

  Clinical Lymphoma Myeloma & Leukemia · 2025-08-28

• Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer

  Cancer Cell · 2025-08-28 · 22 citations

• POSTER: AML-420 Phase 1 Trial of Azacitidine, Venetoclax, and Allogeneic NK Cells in Acute Myeloid Leukemia (ADVENT-AML): Results From Dose-Escalation Phase

  Clinical Lymphoma Myeloma & Leukemia · 2025-08-28

• Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax

  Leukemia · 2025-08-14 · 2 citations

• Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia

  Blood Advances · 2025-08-05 · 3 citations

• 263P A phase Ib dose-escalation trial of gemcitabine and nab-paclitaxel in combination with lixumistat in patients with advanced pancreatic cancer (COMBAT-PC)

  Annals of Oncology · 2025-07-01

• Erratum: Association of Emotional Exhaustion With Career Burnout Among Early-Career Medical Oncologists: A Single-Institution Study

  JCO Oncology Practice · 2025-05-30

• Survival Benefit of Palliative Oophorectomy for Patients With Ovarian Metastasis From Baseline Metastatic Gastric Adenocarcinoma

  Journal of Clinical Oncology · 2025-05-30 · 1 citations

• Association of gut microbiota with therapy efficacy and prognosis in biliary tract cancer.

  Journal of Clinical Oncology · 2025-05-28